Organon & Co. (OGN)
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
- Ticker
- OGN
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Market cap
- $3.64B
- 52-week range
- $5.69 - $13.88
Valuation
- Share price
- $13.87 (close of Nov 6, 2026)
- P/E (TTM)
- 17.34x
- Price to book
- 3.05x
- Price to free cash flow
- 5.40x
- Enterprise value
- $10.74B
- Book value per share
- $4.54
Price performance
| Period | Change |
|---|---|
| 1 day | +0.58% |
| 5 days | +0.22% |
| 1 month | +0.95% |
| 3 months | +2.36% |
| 6 months | +3.43% |
| Year to date | +93.44% |
| 1 year | +106.71% |
| 3 years | +10.43% |
| 5 years | -61.77% |
| All time | -58.29% |
Short interest
- As of
- Oct 15, 2026
- Short % of float
- 8.14%
- Shares short
- 18.82M
- Days to cover
- 8.61
- Change since prior report
- -0.76%
- Source
- FINRA consolidated short interest
Members of Congress who disclosed OGN trades
Super investors holding OGN
Kahn Brothers (Kahn Brothers Group) · Ken Griffin (Citadel)
Profitability and growth
- Return on equity
- 24.87%
- Return on invested capital
- 7.35%*
- Return on assets
- 1.45%
- Return on capital employed
- 8.87%*
- Gross margin
- 53.30%
- Net margin
- 3.01%
- EBITDA margin
- 20.75%
- Revenue growth
- -2.92%
- Net income growth
- -78.36%
- Free cash flow growth
- -29.58%
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 18.53%
- Current ratio
- 2.02x
- Net debt to EBITDA
- 5.49x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- Revenue
- $6.22B
- Cost of revenue
- $2.90B
- Gross profit
- $3.31B
- EBITDA
- $1.29B
- Net income
- $187.00M
- Earnings per share
- $0.72
- Research and development
- $366.00M
- Interest expense
- $504.00M
- Shares outstanding
- 259.50M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $6.22B | $3.31B | $187.00M | $0.72 |
| 2024-12-31 | $6.40B | $3.71B | $864.00M | $3.36 |
| 2023-12-31 | $6.26B | $3.75B | $1.02B | $4.01 |
| 2022-12-31 | $6.17B | $3.88B | $917.00M | $3.61 |
| 2021-12-31 | $6.30B | $3.92B | $1.35B | $5.33 |
| 2020-12-31 | $6.53B | $4.41B | $2.16B | $8.52 |
| 2019-12-31 | $7.78B | $5.50B | $3.22B | $12.69 |
| 2018-12-31 | $9.78B | $5.08B | $2.15B | $8.51 |
| 2017-12-31 | $10.50B | $5.91B | $1.80B | $7.11 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 53.30% | 3.01% | 24.87% | 7.35%* |
| 2024-12-31 | 58.02% | 13.49% | 183.05% | 14.19%* |
| 2023-12-31 | 59.84% | 16.33% | - | 13.81%* |
| 2022-12-31 | 62.84% | 14.85% | - | 16.69%* |
| 2021-12-31 | 62.21% | 21.43% | - | 20.48%* |
| 2020-12-31 | 67.56% | 33.07% | 39.37% | 40.89%* |
| 2019-12-31 | 70.76% | 41.38% | 45.74% | - |
| 2018-12-31 | 52.00% | 22.02% | 33.92% | - |
| 2017-12-31 | 56.30% | 17.15% | - | - |
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $574.00M | $8.63B |
| 2024-12-31 | $675.00M | $8.86B |
| 2023-12-31 | $693.00M | $8.75B |
| 2022-12-31 | $706.00M | $8.90B |
| 2021-12-31 | $737.00M | $9.13B |
| 2020-12-31 | $12.00M | - |
| 2019-12-31 | $319.00M | $138.00M |
| 2018-12-31 | $244.00M | $34.00M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $538.00M | $77.00M |
| 2024-12-31 | $764.00M | $105.00M |
| 2023-12-31 | $548.00M | $101.00M |
| 2022-12-31 | $662.00M | $75.00M |
| 2021-12-31 | $1.97B | $59.00M |
| 2020-12-31 | $2.03B | $40.00M |
| 2019-12-31 | $2.93B | $41.00M |
| 2018-12-31 | $3.59B | $56.00M |
| 2017-12-31 | $3.33B | $56.00M |
Dividend history
- Most recent payment
- Aug 14, 2026
- Paid in the last twelve months
- $0.08
| Payment date | Dividend per share |
|---|---|
| 2026-08-14 | $0.02 |
| 2026-05-11 | $0.02 |
| 2026-02-23 | $0.02 |
| 2025-11-20 | $0.02 |
| 2025-08-15 | $0.02 |
| 2025-05-12 | $0.02 |
| 2025-02-24 | $0.28 |
| 2024-11-12 | $0.28 |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-10-30 | Sep 2026 | $0.95 |
| 2026-07-31 | Jun 2026 | $0.85 |
| 2026-04-30 | Mar 2026 | $0.82 |
| 2026-02-12 | Dec 2025 | $0.71 |
| 2025-11-10 | Sep 2025 | $0.90 |
| 2025-08-05 | Jun 2025 | $0.89 |
| 2025-05-01 | Mar 2025 | $0.83 |
| 2025-02-13 | Dec 2024 | $0.82 |
Filings and sources
- Company website
- organon.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
GSK plc (GSK) · Biogen Inc. (BIIB) · Novo Nordisk A S (NVO) · Bristol Myers Squibb Co (BMY) · Pfizer Inc (PFE) · Gilead Sciences, Inc. (GILD) · Amgen Inc (AMGN) · AstraZeneca plc (AZN)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades